KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program
– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system – CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease … [Read more…]
